Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho
Globe Newswire•11/11/2026•08:44 ET
2
Key Highlights
- ➤Akari appoints Vatnak Vat-Ho as Chief Business Officer.
- ➤AKTX-101 IND-enabling studies aim for first-in-human trial by mid-2027.
- ➤AKTX-101 targets Trop2 with Akari’s proprietary PH1 spliceosome-modulating payload.
- ➤Akari is developing AKTX-102 targeting CEACAM5 across multiple solid tumors.
Discussion highlights Vat-Ho’s oncology business development experience, his decision to join Akari and the potential of the Company’s novel PH1 payload platform
TAMPA, Fla. and LONDON, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing disrupting payload, today announced its participation in a Virtual Investor “What This Means” segment featuring Vatnak Vat-Ho, the Company’s newly appointed Chief Business Officer.
Get started
Create a free account to read the full story.